Financial Performance - The company reported a net loss of 77.3million,or(1.32) per common share, for the year ended December 31, 2024, compared to a net loss of 73.8million,or(1.85) per common share, in 2023[12]. - Total revenues for 2024 were 16.1million,including8.1 million in royalty revenues and 8.0millionfromthesaleofroyaltyrights[15].−Researchanddevelopmentexpensesincreasedto58.7 million for the year ended December 31, 2024, compared to 49.6millionin2023,primarilyduetoclinicaltrial−relatedexpenses[12].−Generalandadministrativeexpensesdecreasedto25.4 million in 2024 from 32.6millionin2023,attributedtoloweremployeecostsandreducedlegalandconsultingfees[12].−Aworkforcereductionofapproximately20128.4 million, sufficient to fund operations into the second half of 2026[12]. - Total current assets increased to 132,440millioninDecember2024,upfrom124,604 million in December 2023, representing a growth of 6.5%[17]. - Cash and cash equivalents rose significantly to 19,473million,comparedto9,664 million in the previous year, marking an increase of 101.4%[17]. - Total assets decreased to 157,181millionfrom173,726 million, a decline of 9.6%[17]. - Total stockholders' equity slightly decreased to 120,751millionfrom125,704 million, reflecting a decline of 4.0%[17]. Liabilities and Deficits - Total liabilities decreased to 36,430millioninDecember2024from48,022 million in December 2023, a reduction of 24.2%[17]. - Accounts payable increased to 4,859million,upfrom3,896 million, indicating a rise of 24.6%[17]. - Accumulated deficit widened to (363,556)millioninDecember2024from(286,225) million in December 2023, an increase of 27.1%[17]. - Operating lease liabilities, net of current portion, decreased to 18,650millionfrom20,099 million, a decrease of 7.2%[17]. - Deferred revenues were reported as zero in December 2024, down from 7,660millioninDecember2023[17].ClinicalDevelopments−PyxisOncologyachievedaconfirmed5021.0 million related to in-process research and development intangible asset for PYX-107[12].